OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition.
about
OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
OL3, a novel low-absorbed TGR5 ...... tivation and DPP-4 inhibition.
@en
OL3, a novel low-absorbed TGR5 ...... tivation and DPP-4 inhibition.
@nl
type
label
OL3, a novel low-absorbed TGR5 ...... tivation and DPP-4 inhibition.
@en
OL3, a novel low-absorbed TGR5 ...... tivation and DPP-4 inhibition.
@nl
prefLabel
OL3, a novel low-absorbed TGR5 ...... tivation and DPP-4 inhibition.
@en
OL3, a novel low-absorbed TGR5 ...... tivation and DPP-4 inhibition.
@nl
P2093
P2860
P356
P1476
OL3, a novel low-absorbed TGR5 ...... tivation and DPP-4 inhibition.
@en
P2093
Jian-Hua Shen
Meng-Meng Ning
Qing-An Zou
Shan-Yao Ma
Yang-Liang Ye
P2860
P2888
P304
P356
10.1038/APS.2016.27
P577
2016-06-06T00:00:00Z
P6179
1019214699